Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28123709 | 0.98 | FABP3 (0.44) | FABP3ADRA1ALMNAESR1ADORA3 | |
| Hydrochloric Acid SCHEMBL17143223 | 0.98 | FABP3 (0.44) | FABP3ADRA1ALMNAESR1ADORA3 | |
| SCHEMBL25857265 | 0.91 | SMN1; SMN2 (0.46) | FABP3ADRA1ALMNAESR1ADORA3 | |
| SCHEMBL1692413 | 0.88 | LMNA (0.49) | FABP3ADRA1ALMNAESR1ADORA3 | |
| Fumaric Acid SCHEMBL9244675 | 0.87 | FABP3 (0.41) | FABP3ADRA1ALMNAESR1ADORA3 | |
| SCHEMBL28733155 | 0.87 | FABP3 (0.43) | FABP3ADRA1ALMNAESR1ADORA3 | |
| Methacrylic Acid SCHEMBL28838877 | 0.87 | FABP3 (0.41) | FABP3ADRA1ALMNAESR1ADORA3 | |
| SCHEMBL14448025 | 0.86 | FABP3 (0.42) | FABP3ADRA1ALMNAESR1ADORA3 | |
| SCHEMBL28053308 | 0.85 | FABP3 (0.40) | FABP3ADRA1ALMNAESR1ADORA3 | |
| Acrylamide SCHEMBL27991709 | 0.85 | FABP3 (0.40) | FABP3ADRA1ALMNAESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| US-20260097095-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | MEPSGEN CO LTD (KR) | 2026-04-09 | — | — | US | claimed |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PHARMOSA BIOPHARM INC (TW) | 2026-03-12 | — | — | US | claimed |
| EP-4706644-A1 | RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES COMPRISING CHOLESTEROL | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| EP-4706645-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | Mepsgen Co., Ltd. (KR) | 2026-03-11 | — | — | EP | claimed |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | PHARMOSA BIOPHARM INC. (TW) | 2026-02-17 | — | — | US | claimed |
| EP-4691619-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | Mepsgen Co., Ltd. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20260021485-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | MEPSGEN CO LTD (KR) | 2026-01-22 | — | — | US | claimed |
| WO-2025230917-A1 | METHODS FOR TREATING SYSTEMIC SCLEROSIS AND FROST BITE BY INHALATION THERAPY | PHARMOSA BIOPHARM INC. (TW) | 2025-11-06 | — | — | WO | claimed |
| EP-4626483-A1 | SURFACE MODIFIED CARBON NANOTUBES AND USES THEREOF | Luna Labs USA, LLC (US) | 2025-10-08 | — | — | EP | claimed |
| WO-2006006161-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2006-01-19 | — | — | WO | claimed |
| WO-2005116043-A1 | NOVEL AMPHIPHILIC COMPOUNDS, PREPARATION METHOD THEREOF AND APPLICATIONS OF SAME | UNIVERSITE D'AVIGNON ET DES PAYS DE VAUCLUSE (FR) | 2005-12-08 | — | — | WO | claimed |
| US-20050107287-A1 | Treatment of cancers by inhalation of stable platinum-containing formulations | PILKIEWICZ FRANK G (US) | 2005-05-19 | — | — | US | claimed |
| EP-1305322-A4 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | DPHARM LTD (IL) | 2005-04-13 | — | — | EP | claimed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | claimed |
| JP-2004505898-A | — | — | 2004-02-26 | — | — | JP | claimed |
| EP-1305322-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-Pharm Ltd. (IL) | 2003-05-02 | — | — | EP | claimed |
| WO-2002011666-A2 | DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF | D-PHARM LTD. (IL) | 2002-02-14 | — | — | WO | claimed |
| EP-1049491-A1 | GENE THERAPY OF TUMORS USING NON-VIRAL DELIVERY SYSTEM | Perez-Soler, Roman (US) | 2000-11-08 | — | — | EP | claimed |
| WO-1999034835-A1 | GENE THERAPY OF TUMORS USING NON-VIRAL DELIVERY SYSTEM | PEREZ SOLER ROMAN (US) | 1999-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021485-A1 | MICROFLUIDIC DEVICE FOR MANUFACTURING UNIFORM NANOPARTICLES | CD44, CAD, SLCO4C1 | FABP3 133/4885ADRA1A 182/4885LMNA 3354/4885 |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PTGER2, PTGER1, PTGIR | FABP3 260/4885ADRA1A 338/4885LMNA 2537/4885 |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | LIPA, NSF, SLC26A3 | FABP3 1504/4885ADRA1A 487/4885LMNA 1501/4885 |
| US-20260097095-A1 | PEGYLATED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN NANOPARTICLES | LDLR, CETP, APOL1 | FABP3 711/4885ADRA1A 2638/4885LMNA 2329/4885 |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | SLC26A3, LIPA, NSF | FABP3 1487/4885ADRA1A 455/4885LMNA 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.